11
Participants
Start Date
January 31, 2018
Primary Completion Date
May 22, 2018
Study Completion Date
August 24, 2020
ETBX-051; adenoviral brachyury vaccine
immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
National Institutes of Health Clinical Center, Bethesda
National Cancer Institute (NCI)
NIH